Natera, Inc. (NASDAQ:NTRA) CFO Sells $59,068.64 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 496 shares of the stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $119.09, for a total value of $59,068.64. Following the sale, the chief financial officer now owns 74,314 shares of the company’s stock, valued at approximately $8,850,054.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The shares were sold at an average price of $120.76, for a total value of $73,422.08.
• On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The stock was sold at an average price of $99.65, for a total value of $185,946.90.
• On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $102.77, for a total transaction of $127,229.26.
• On Thursday, July 25th, Michael Burkes Brophy sold 690 shares of Natera stock. The stock was sold at an average price of $105.29, for a total transaction of $72,650.10.

Natera Trading Down 1.1 %

Shares of NTRA stock opened at $118.65 on Thursday. The stock has a 50 day simple moving average of $123.43 and a 200-day simple moving average of $111.03. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $133.54. The company has a market cap of $14.57 billion, a price-to-earnings ratio of -38.03 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company’s revenue was up 58.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.97) earnings per share. On average, equities research analysts expect that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Natera

Several large investors have recently bought and sold shares of NTRA. Itau Unibanco Holding S.A. acquired a new stake in shares of Natera in the second quarter worth approximately $28,000. Quarry LP grew its holdings in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after buying an additional 108 shares during the last quarter. Tobam purchased a new position in shares of Natera in the second quarter worth about $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in Natera during the first quarter worth about $83,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on NTRA shares. Robert W. Baird upped their target price on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Leerink Partners raised their price objective on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Morgan Stanley lifted their target price on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Thursday, October 17th. Finally, Stephens reaffirmed an “overweight” rating and issued a $125.00 price objective on shares of Natera in a report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $124.44.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.